MaxCyte Q2 revenue up 15% to $10.4M; core revenue down 9% to $7.6M; SPL revenue jumps 279%

MAXCYTE, INC.

2024-Q2 EPS reported -$0.18 revenue$21,770,000

Total revenue $10.4M (+15% YoY); core business revenue $7.6M (-9% YoY); SPL program-related revenue $2.9M (+279% YoY).
Net loss narrowed to $9.4M from $10.5M in Q2 2023; EBITDA loss $10.9M vs $12.0M.
Signed five new SPLs YTD including Legend Biotech (May) and Be Biopharma (Mar); total SPL partners now 28.
Ended Q2 with $199.8M cash; now expects FY2024 ending cash at least $180M, up from prior $175M guidance.
Raised FY2024 SPL revenue guidance to ~$6M; core business revenue guidance reaffirmed flat to 5% growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.